Prevalence and temporal trends of potential macrolide and quinolone resistance-associated mutations in Mycoplasma genitalium in St. Petersburg, Russia
| Mutations | No. of MG-positive samples* with mutations (CI95%) | Ptrend | ||
| 2007–2008 (n=21) | 2013–2017 (n=64) | 2018–2020 (n=60) | ||
| Macrolide resistance-associated mutations | 0 (0 (0 to 15.5)) | 5 (7.8 (3.4 to 17.0)) | 15 (25.0 (15.8 to 37.2)) | 0.0009 |
| Quinolone resistance-associated mutations | 0 (0 (0 to 15.5)) | 5 (7.8 (3.4 to 17.0)) | 8 (13.3 (6.9 to 24.2)) | 0.0605 |
| Macrolide plus quinolone resistance-associated mutations | 0 (0 (0 to 15.5)) | 2 (3.1 (0.6 to 10.7)) | 6 (10.0 (4.7 to 20.1)) | 0.0447 |
*Cervicovaginal swab specimens from women and urethral swab specimens (also some few urine specimens) from men.